Онкопедиатрия. 2014; 1: 49-53
Результаты комбинированного лечения детей и подростков с остеосаркомой
Аннотация
Проведен анализ результатов комбинированного лечения 122 детей в возрасте 5–17 лет с остеосаркомой, из них с локализованными формами 72,6%, с генерализованными — 27,4%. Дети пролечены в НИИ онкологии им Н.Н. Петрова в период 1980–2010 гг. Длительность наблюдения составила от 13 до 378 мес (медиана 63,2 мес). Результаты лечения зависели от распространенности процесса, вида полихимиотерапии и объема оперативного пособия. Наиболее высокие результаты получены у больных с органосохраняющими оперативными пособиями, которые могут быть выполнены у 80% пациентов.
Список литературы
1. Иванова Н.М., Савлаев К.Ф., Шварова А.В. и др. Предварительные результаты высокодозной терапии метотрексатом остеосаркомы у детей. Детская онкология. 2006; 4: 30–35.
2. Мачак Г.Н., Соколовский В.А., Соловьёв Ю.Н. и др. Роль предоперационной химиотерапии в органосохраняющем лечении остеосарком конечностей. Вместе противрака. 2007; 3–4: 9–16.
3. Dotan A., Dadia S., Bickels J. et al. Expandable endoprosthesis for limb-sparing surgery in children: long-term results. J Child Orthop. 2010; 4 (5): 391–400.
4. Ferrari S., Bertoni F., Mercuri M., Picci P. et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Annals of Oncology. 2001; 12: 1145–1150.
5. Lewis I.J., Nooij M.A., Whelan J. et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 200 limb-sparing surgery affect survival in osteosarcoma.Clin Or thop Relat Res. 2010; 468 (11): 2854–2859.
6. Grimer R.J., Taminiau M.A., Cannon S.R. Surgical outcomes in osteosarcoma. J Bone Joint Surg Br. 2002; 84 (3): 395–400.
7. Chin T.J., Wang J.W., Chen Y.J. Intraarterialcisplatin and intravenous adriamycin in non- metastatic osteosarcoma of the extremities: a single institution experience in Taiwan. Chang Gung Med J. 2009; 32 (1): 72–80.
8. Hong S., Shin S.J., Jung M. et al. Comparision of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of extremity. Oncology. 2011; 80 (1–2): 107–117.
9. Bacci G., Ferrari S., Longhi A. et al. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Ortop Scand. 2003; 74 (4): 449– 454.
10. Winkler K., Bieling P., Bielack S. et al. Local control and survival from the cooperative osteosarcoma study group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin Orthop. 1991; 270: 79–86.
11. Zalupski M.M., Rankin G., Ryan J.R. et al. Adjuvant therapy of osteosarcoma a phase II trial: Southwest Oncology Group study: 9139. Cancer. 2004; 100 (4): 818–825.
12. Bielack S.S., Kempf-Bielack B., Delling G. et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776– 790.
13. Tunn P.U., Reichardt P. Chemotherapy for osteosarcoma without high-dose methotrexate: a 12-year follow-up on 53 patients. Oncologie. 2007; 30 (5): 228–232.
Oncopediatrics. 2014; 1: 49-53
The Results of Combined Therapy in Children and Adolescents with Osteosarcoma
Abstract
The combined treatment results of 122 pediatric (5–17 years) osteosarcoma patients receiving therapy in N.N.Petrov Oncology Research Institute in 1980–2010 were analyzed. Among the patients, 72,6% had localized form and 27,4% had metastatic disease. The median follow-up was 63,2 (13–378) months. Treatment results correlated with process dissemination, chemotherapy regimen and surgical procedure used. The best results were achieved in patients receiving organ-sparing surgery, which can be performed in, approximately, 80% of the patients.
References
1. Ivanova N.M., Savlaev K.F., Shvarova A.V. i dr. Predvaritel'nye rezul'taty vysokodoznoi terapii metotreksatom osteosarkomy u detei. Detskaya onkologiya. 2006; 4: 30–35.
2. Machak G.N., Sokolovskii V.A., Solov'ev Yu.N. i dr. Rol' predoperatsionnoi khimioterapii v organosokhranyayushchem lechenii osteosarkom konechnostei. Vmeste protivraka. 2007; 3–4: 9–16.
3. Dotan A., Dadia S., Bickels J. et al. Expandable endoprosthesis for limb-sparing surgery in children: long-term results. J Child Orthop. 2010; 4 (5): 391–400.
4. Ferrari S., Bertoni F., Mercuri M., Picci P. et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Annals of Oncology. 2001; 12: 1145–1150.
5. Lewis I.J., Nooij M.A., Whelan J. et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 200 limb-sparing surgery affect survival in osteosarcoma.Clin Or thop Relat Res. 2010; 468 (11): 2854–2859.
6. Grimer R.J., Taminiau M.A., Cannon S.R. Surgical outcomes in osteosarcoma. J Bone Joint Surg Br. 2002; 84 (3): 395–400.
7. Chin T.J., Wang J.W., Chen Y.J. Intraarterialcisplatin and intravenous adriamycin in non- metastatic osteosarcoma of the extremities: a single institution experience in Taiwan. Chang Gung Med J. 2009; 32 (1): 72–80.
8. Hong S., Shin S.J., Jung M. et al. Comparision of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of extremity. Oncology. 2011; 80 (1–2): 107–117.
9. Bacci G., Ferrari S., Longhi A. et al. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Ortop Scand. 2003; 74 (4): 449– 454.
10. Winkler K., Bieling P., Bielack S. et al. Local control and survival from the cooperative osteosarcoma study group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin Orthop. 1991; 270: 79–86.
11. Zalupski M.M., Rankin G., Ryan J.R. et al. Adjuvant therapy of osteosarcoma a phase II trial: Southwest Oncology Group study: 9139. Cancer. 2004; 100 (4): 818–825.
12. Bielack S.S., Kempf-Bielack B., Delling G. et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776– 790.
13. Tunn P.U., Reichardt P. Chemotherapy for osteosarcoma without high-dose methotrexate: a 12-year follow-up on 53 patients. Oncologie. 2007; 30 (5): 228–232.
